Phase 1 BIO 300 Oral Suspension
NCT06741345
Recruiting
This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug when given as daily doses over 14 days. The study will enroll three cohorts each receiving a different daily dose: 2000 mg, 3000 mg, or 4000 mg. A fourth group may be added depending on results on the first three cohorts. Each cohort will include 10 participants (5 men, 5... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/28/2025
Locations: Nucleus Network, LLC, Saint Paul, Minnesota
Conditions: Healthy Volunteer Study
Register for Updates
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
NCT06747884
Recruiting
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
07/28/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
Register for Updates
SLV-154 Treatment of Metastatic Solid Tumors
NCT06771219
Recruiting
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +3 locations
Conditions: Squamous Cell Cancer of Head and Neck (SCCHN), NSCLC, SCLC, Cervical Cancer Metastatic, Breast Cancer Metastatic, Endometrial Cancer, Ovarian Cancer, Urothelial Cancer, Sarcoma, Thyroid Cancer
Register for Updates
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Johnson Dermatology, Fort Smith, Arkansas +112 locations
Conditions: Hidradenitis Suppurativa
Register for Updates
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT06805617
Recruiting
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
Register for Updates
Optimizing Strength Training in Older Adults
NCT06812143
Recruiting
The objective of the current study is to determine whether lifting lighter loads close to failure improves strength training adaptations and function in older adults. The main questions it aims to answer are: 1. The effect of light loads on physical function 2. The effect of light loads on muscle mass, power, and strength Researchers will compare a light-load, high-repetition program to a standard strength training program. Participants will perform supervised strength training twice per week... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/28/2025
Locations: Exercise & Aging Lab, Queens College, Flushing, New York
Conditions: Aging
Register for Updates
An Efficacy and Safety Study With Integrated Pharmacokinetics (PK) and Pharmacodynamic (PD) Assessment to Compare the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (RMS)
NCT06847724
Recruiting
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/28/2025
Locations: Sandoz Investigational Site, Maitland, Florida +11 locations
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Preventing Type 2 Diabetes in Black Emergent Adult
NCT06848244
Recruiting
Black Americans are disproportionately affected by diabetes, with nearly double the rates of type 2 diabetes mellitus (T2DM), compared to non-Hispanic White adults. Though numerous factors affect these disparities, one modifiable risk factor may be that of binge eating (BE), which increases risk for binge-eating disorder (BED), which is associated with severe obesity, and often precedes a T2DM diagnosis, beginning in childhood or adolescence. Nearly 30% of Black women with obesity report binge e... Read More
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
07/28/2025
Locations: UNC-Chapel Hill, Chapel Hill, North Carolina
Conditions: Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Register for Updates
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Southern California Clinical Research, Santa Ana, California +52 locations
Conditions: Obesity
Register for Updates
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
NCT06868212
Recruiting
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Acuro Research Inc, Little Rock, Arkansas +22 locations
Conditions: Chronic Spontaneous Urticaria (CSU)
Register for Updates
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/28/2025
Locations: Northwestern Memorial Hospital, Evanston, Illinois +16 locations
Conditions: ANCA Associated Vasculitis (AAV)
Register for Updates
A Study of Paramedic HF Management
NCT06874556
Recruiting
The purpose of this research is to see if having community paramedic (CP) visit patients at home to manage their heart failure help them stay out of the hospital and improve their overall health compared to standard care. The investigators want to find out if their approach is better for patients in terms of their quality of life, hospital stays, emergency visits, and cost. The investigators are also looking to see how happy patients and doctors are with this method and if it's a practical and s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Heart Failure
Register for Updates